Articles On Imugene (ASX:IMU)

The company’s preclinical results present an effective treatment against Peritoneal carcinomatosis (PC) from pancreatic ductal adenocarcinoma (PDAC).

Imugene Announced Completion of GMP manufacturing and Toxicology Studies for PD1-Vaxx

Pre-clinical milestones have been met with GMP manufacturing, including final sterile fill and finish as well as processes completed by FDA inspected and qualified contract manufacturing organisations in the US.

Imugene (IMU) will trial its cancer immunotherapy treatment, PD10Vaxx, to patients in North America and Australia The treatment will be trialled on patients with non-small cell lung cancer, which is the most common type of lung cancer The...

Immuno-oncology company Imugene (ASX: IMU) is set to advance its PD1-Vaxx cancer immunotherapy by trialling the treatment in patients with non-small cell lung cancer. In an update to the market, the company said it plans to conduct a new st...

28 Jan 2020 - Immuno-therapy company Imugene (ASX:IMU) report that studies have shown their PD1-Vaxx cancer immunotherapy drug generates high levels of antibodies.

A Smash Hit by Imugene: Received Core US Patent for HER-Vaxx

The health sector was the most successful sector on the ASX in 2019. Various small caps made several breakthroughs including with nerve damage and macular degeneration. While cancer remains one fish that has yet to be fried there are small...

The patent provides method of composition and method of use protection to 2036.

14 Jan 2020 - Immuno-therapy company Imugene (ASX:IMU) has received the US patent for its HER-VAxx cancer treatment.

Imugene (IMU) has received a Notice of Grant from the United States Patent and Trademark Office to protect its HER-Vaxx cancer immunotherapy HER-Vaxx is a B-cell immunotherapy designed to treat tumours that over-express the HER-2/neu rece...

Imugene (ASX: IMU) has received a strong boost in protecting its intellectual property for the next 16 years after the US Patent and Trademark Office (USPTO) granted the immuno-oncology company with a patent for its HER-Vaxx cancer immunoth...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

You don’t need a PhD to run a biotech, but sometimes it helps, as these companies deal in one of the most complicated mysteries still to be solved today: the human body. Biotech CEOs and chairs tend to be the cross-over scientists. However,...

Australia-based clinical stage immuno-oncology player, Imugene Limited (ASX: IMU) has recently announced the appointment of Surgeon Scientist, Dr. Rebecca Auer to its newly formed OV (oncolytic virotherapy) Scientific Advisory Board. Dr. A...

Dr. Auer heads a research laboratory and is the principle investigator in related clinical trials.

New Zealand’s medicines regulator has recommended the country fall in line with Australia’s new codeine restrictions, and pharmaceutical companies are backing the decision. Yesterday, Medsafe recommended that all medications containing code...

Clinical-stage immuno-oncology player, Imugene Limited (ASX: IMU) recently notified that it has received firm commitments for a capital raising of up to $24.6 million that involves Placement of up to 683 million ordinary shares to sophistic...

The placement raised A$24.6 million and was well supported by existing investors and new sophisticated and institutional investors.

Paul Hopper is an Australian biotech entrepreneur who has been associated with a number of biotechnology companies.

Biopharmaceutical company Imugene is looking to raise up to $24.6 million in an equity raising targeted at institutions. 

The company’s securities are in a trading halt until Monday, December 2, or when an announcement is made to the market.

It can be difficult to swallow banker-sized executive salaries in an earnest but yet-to-achieve small cap. But there are as many moments when CEOs, managing directors, and executive chairmen and women earn their keep. We uncovered the top 1...

In a recent ASX update, Australian headquartered Imugene Limited (ASX: IMU) has notified that CF33 oncolytic virus CheckVacc and Vaxinia constructs have completed clinical grade GMP batches at the manufacturing facility, City of Hope Center...

CF33 is a highly potent, chimeric oncolytic poxvirus – a poxvirus refers to a large group of DNA viruses that cause smallpox and similar infectious diseases in vertebrates.

Clinical stage immuno-oncology company Imugene (ASX:IMU) has announced the appointment of Professor Prasad S. Adusumilli, MD FACS FCCP, to its newly formed oncolytic virotherapy Scientific Advisory Board.

The company’s vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments – this vision is backed by a growing body of clinical evidence and peer-reviewed research.

Imugene Limited (ASX: IMU) jumped 18 per cent on ASX following the completion of oncolytic virus CF33 and Vaxinia Pty Ltd acquisition on 18th November 2019. IMU closed the trading session at $0.053 with ~259 million shares in rotation on 18...

“We are delighted to be able to complete the acquisition of Vaxinia Pty Ltd and City of Hope licence of such a promising next-generation oncolytic virus,” says MD and CEO Leslie Chong.

Clinical-stage biotech player Imugene Limited (ASX: IMU) soared ~27 per cent on the ASX today, settling the day’s trade at $0.033 on 11th November 2019. The stock has delivered a substantial return of ~53 per cent in the last six months, dr...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Australian immuno-oncology company, Imugene Limited (ASX: IMU) is developing a pipeline of mimotope-based B-cell immunotherapies against oncology targets that could replace or be used in combination with monoclonal antibodies. The company i...

Imugene is planning two separate Phase 1 clinical trials in 2020 to test a CheckVacc construct and a Vaxinia construct of the CF33 oncolytic virus.

There are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so — but less than 25 are anywhere close to their ultimate dream of bringing a drug successfully to market, a Stockhead analysis has found. Ta...

Biotechnology firm headquartered in Australia, Imugene Limited (ASX: IMU) is a clinical stage immuno-oncology player that develops novel immunotherapies to treat and eradicate cancerous tumours. The company’s unique platform technologies ho...

As per latest update from Imugene Limited (ASX: IMU), the prominent City of Hope researchers have received a Grant of USD 564,173 from the US Department of Defense to study the company’s Oncolytic Virotherapy (OV) CF33 in gastric cancer. Ma...

The proposal for the exclusive license of patents covering the CF33 OV technology will be put to Imugene (ASX:IMU) shareholders for their approval at an Extraordinary Meeting of Shareholders to be held on 18 November.

Clinical stage immuno-oncology company Imugene (ASX:IMU) has announced that City of Hope researchers have received a grant from the US Department of Defense Grant related to the use of its technology.

ASX-listed clinical stage immuno-oncology firm, Imugene Limited (ASX: IMU) has released an update on the preliminary clinical development plan for the intended exclusive license of the patents encompassing the oncolytic virus technology, CF...

The grant focuses on the area of gastric cancer, a disease that disproportionately affects US military service members, veterans, and their beneficiaries.

Immuno-oncology company Imugene’s (ASX: IMU) oncolytic virotherapy (OV) drug will receive a boost after City of Hope researchers received a US Department of Defense grant to study the drug in gastric cancer sufferers. City of Hope researche...

Botanix Pharmaceuticals’ (ASX:BOT) shares have halved after its anti-acne drug failed its clinical trial. If you read most of the company’s announcement and you’d would have thought the 368 patient trial was a success. Its drug, BTX 1303, w...

A US Department of Defense Grant titled Discovery of Immune Biomarkers That Predict Response to a Novel Chimeric Immuno-Oncolytic Virus Encoding Anti-PD-L1 in Gastric Cancer Peritoneal Carcinomatosis has been awarded to prominent City of Ho...

As the market players are aware, performance of broader Australian markets is expected to be influenced by the health of global economy. Also, performance of global markets can influence the performance of Australian equities. Any sort of e...

Australia-based clinical stage immuno-oncology firm, Imugene Limited (ASX: IMU) is involved in the development of various new and novel immunotherapies that attempt to stimulate the patient’s immune system to eradicate and treat tumours. Im...

Two separate Phase 1 clinical trials will be conducted in 2020 to test a CheckVacc construct and a Vaxinia construct of the oncolytic virus.

Drug development company Noxopharm (ASX: NOX) is growing more optimistic about the use of its Veyonda treatment on patients with late-stage prostate cancer. NOX provided an interim update on its DARRT-1 clinical trial, where patients are gi...

Imugene Limited (ASX:IMU) has provided a promising update on the preliminary clinical development plan (CDP) for the proposed exclusive license of the patents covering the CF33 oncolytic virus technology, which is subject to shareholders’ a...

A pioneer in the operating room and in the laboratory, Dr Fong, The Sangiacomo Family Chair in Surgical Oncology and chair of The City of Hope Dept of Surgery, is a recognised expert in liver and pancreatic cancer.